Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group
Authors:
- on behalf of the EURECCA Breast Cancer GroupOGon behalf of the EURECCA Breast Cancer Group
- Marloes G. M. DerksMDMarloes G. M. Derks
- Denise E. HillingDHDenise E. Hilling
- John BroggioJBJohn Broggio
- Maciej TrojanowskiMTMaciej Trojanowski
Open Access
- 7 June 2018
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (1) , 121-129
Abstract
Older patients are poorly represented in breast cancer research and guidelines do not provide evidence based recommendations for this specific group. We compared treatment strategies and survival outcomes between European countries and assessed whether variance in treatment patterns may be associated with variation in survival. Population-based study including patients aged ≥ 70 with non-metastatic BC from cancer registries from the Netherlands, Belgium, Ireland, England and Greater Poland. Proportions of local and systemic treatments, five-year relative survival and relative excess risks (RER) between countries were calculated. In total, 236,015 patients were included. The proportion of stage I BC receiving endocrine therapy ranged from 19.6% (Netherlands) to 84.6% (Belgium). The proportion of stage III BC receiving no breast surgery varied between 22.0% (Belgium) and 50.8% (Ireland). For stage I BC, relative survival was lower in England compared with Belgium (RER 2.96, 95%CI 1.30–6.72, P < .001). For stage III BC, England, Ireland and Greater Poland showed significantly worse relative survival compared with Belgium. There is substantial variation in treatment strategies and survival outcomes in elderly with BC in Europe. For early-stage BC, we observed large variation in endocrine therapy but no variation in relative survival, suggesting potential overtreatment. For advanced BC, we observed higher survival in countries with lower proportions of omission of surgery, suggesting potential undertreatment.Keywords
This publication has 32 references indexed in Scilit:
- Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trialThe Breast, 2013
- Trends of population-based breast cancer survival in Germany and the US: Decreasing discrepancies, but persistent survival gap of elderly patients in GermanyBMC Cancer, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?British Journal of Cancer, 2011
- Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in DenmarkJNCI: Journal of the National Cancer Institute, 2011
- On Estimation in Relative SurvivalBiometrics, 2011
- Variation in ‘standard care’ for breast cancer across Europe: A EUROCARE-3 high resolution studyEuropean Journal of Cancer, 2010
- Cancer patient preferences for quality and length of lifeCancer, 2008
- An approach to estimation in relative survival regressionBiostatistics, 2008
- Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane reviewBritish Journal of Cancer, 2007